Health Care · Pharmaceutical Preparations

OCUL OCULAR THERAPEUTIX, INC SEC Filings & Insider Trading Activity 2026

company
CIK 1393434138 filings
Russell 2000

OCUL at a glance

OCULAR THERAPEUTIX, INC (OCUL, SEC CIK 1393434) filed its latest 10-K annual report on February 5, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and Form 4 insider filings as recently as November 10, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), OCULAR THERAPEUTIX, INC (OCUL) reported revenue of $52.0 million (down 18.5% from FY2024) and a net loss of $265.9 million. Diluted EPS was -$1.42.
  • As of September 30, 2026, 29 institutional investment managers tracked by SignalX reported holding OCULAR THERAPEUTIX, INC (OCUL) shares worth $464.9 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Saroj Namrata on November 5, 2026 of 35,370 shares at $6.55 per share.
  • In the last 90 days, OCUL insiders reported 0 open-market purchases ($0) and 10 open-market sales ($1.0M) on Form 4, a net sale of $1.0M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$52.0M
−18.5% vs prior year
Insiders · 90 days
0 buys · 10 sells
Net −$1.0M
13F holders
29 funds
$464.9M · +0 vs prior quarter
Latest 8-K
Nov 9, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business: Integrated biopharmaceutical company developing ELUTYX hydrogel-based ocular drug delivery platform for retina diseases
  • New emphasis on AXPAXLI (OTX-TKI), a Phase 3 axitinib intravitreal hydrogel implant targeting wet AMD and diabetic retinal disease with registrational trials SOL and HELIOS
  • Strategic shift: Expansion from commercial DEXTENZA steroid to late-stage novel AXPAXLI candidate with accelerated NDA timeline via 505(b)(2) pathway
  • Quantitative highlight: SOL-1 trial randomized 344 subjects by Dec 2024; SOL-R trial randomized 631 subjects by Nov 2025 across US, Argentina, India, Australia
  • Noteworthy fact: ELUTYX technology used in 5 million+ patients since 1992; DEXTENZA implanted in nearly 750,000 eyes with adverse events in 0.02% patients

Risk Factors

  • Regulatory risk: FDA may require additional trials delaying AXPAXLI approval for wet AMD and diabetic retinal disease
  • Macroeconomic exposure: $82.5M debt under Barings Credit Facility requires minimum liquidity $20M, royalty fee 3.5% of DEXTENZA sales
  • Operational vulnerability: reliance on scaling manufacturing and commercial capabilities for DEXTENZA and AXPAXLI commercialization
  • Competitive risk: uncertainty if AXPAXLI achieves sufficient market acceptance against other treatments for wet AMD and NPDR
  • Financial risk: net losses $265.9M in 2025, accumulated deficit $1.157B, may require additional capital raising causing dilution or operational constraints

Management Discussion & Analysis

  • Revenue $51.9M in 2025 vs $63.7M in 2024 and $58.4M in 2023, declining due to decreased DEXTENZA sales
  • Net loss widened to $265.9M in 2025 from $193.5M in 2024 and $80.7M in 2023; operating expenses $322.0M in 2025
  • Operating margin negative, reflecting sustained losses and increasing R&D and commercial expenses
  • Cash and cash equivalents $737.1M at Dec 31, 2025; financing activities provided $561.7M in 2025 including $445.6M from 2025 stock offering
  • Management expects cash to fund operations into 2028 but anticipates need for additional funds to commercialize AXPAXLI if approved

AI summary of the OCUL 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • No material risk-factor changes disclosed from the December 31, 2025 Form 10-K
  • Clinical-development risk: AXPAXLI direct program expenses rose to $119,966 through nine months
  • Legal risk: EyePoint litigation settled October 30, 2026 with no financial obligation
  • Liquidity risk: $530,612 cash supports planned operations through 12 months while maintaining $20,000 minimum liquidity
  • Debt risk: $82,474 Barings principal due in 2029 with SOFR plus 6.75% interest terms

Management Discussion & Analysis

  • Quarterly revenue $12.9M, down 11.0% YoY from $14.5M, entirely DEXTENZA product revenue
  • Net loss $94.8M vs $69.4M YoY, operating loss $97.9M vs $68.7M
  • Worst performer DEXTENZA: revenue down $1.6M, GTN provisions 57.7% vs 52.5%
  • Cash and equivalents $530.6M, operating cash use $198.9M for nine months vs $150.6M YoY
  • Outlook: NDA submission targeted Q4 2026, cash expected to fund operations into 2028, R&D expenses expected to increase

AI summary of the OCUL 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 9, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results announced for quarter ended September 30, 2026
  • Full results and management commentary available in Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • Q3 2026 net revenue $12.9M vs $14.5M; net loss widened to $94.8M, or $0.42/share
  • Cash $530.6M supports planned operations into 2028, excluding full manufacturing and commercial scale-up costs
Filed Nov 9, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Riad Sherif, former Novartis and Alcon executive, elected to Class I board seat through 2027 annual meeting
  • Ophthalmology industry expertise added through Oculis Holding AG CEO and Revenio Group board member
Filed Oct 16, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Chief Strategy Officer Sanjay Nayak resigning effective October 16, 2026
  • Departure to become CEO of a privately held company, indicating loss of senior strategic leadership

AI summaries of OCUL 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for OCUL

Don't miss the next OCUL filing

  • Alerts as it files. A push when OCUL files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut OCUL, by share count.
  • Ask anything. An AI agent that reads every OCUL filing and answers with sources.

OCUL alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Sherif RiadANov 6, 2026-
Sherif RiadANov 6, 2026-
Saroj NamrataSellNov 5, 2026$6.55
Anderman ToddSellOct 8, 2026$7.29
Kaiser PeterSellOct 2, 2026$7.05
Heier Jeffrey S.SellOct 2, 2026$7.05
Notman DonaldSellAug 31, 2026$10.24
Dugel PravinGAug 25, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$63.7M$52.0M
Operating Income--$171.8M-$270.0M
Net Income-$80.7M-$193.5M-$265.9M
Op. Margin--269.6%-519.8%
Net Margin--303.7%-511.9%
Balance Sheet
Total Assets$252.1M$457.9M$808.1M
Equity-$315.3M$654.3M
ROE--61.4%-40.6%
Per Share
EPS$-1.02$-1.22$-1.42
Cash Flow
Operating CF--$134.7M-$204.9M
CapEx$6.1M$1.3M$12.0M

Source: XBRL data in OCULAR THERAPEUTIX, INC (OCUL)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate OCUL share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
OCUL shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202629$464.9M
Q2 202629$889.6M
Q1 202630$700.9M
Q4 202527$979.3M
Q3 202527$874.3M
Q2 202528$542.2M
Q1 202525$198.6M
Q4 202420$189.4M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 215 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

OCUL filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 10, 2026--
8-KNov 9, 2026Analysis-
4Nov 9, 2026--
10-QNov 9, 2026Analysis
8-KNov 9, 2026Analysis-
8-KOct 16, 2026Analysis-
4Oct 13, 2026--
4Oct 6, 2026--
4Oct 6, 2026--
4Sep 2, 2026--
4Aug 26, 2026--
4Aug 26, 2026--
4Aug 26, 2026--
4Aug 26, 2026--
10-QAug 3, 2026Analysis
8-KAug 3, 2026Analysis-
4Jun 18, 2026--
4Jun 12, 2026--
4Jun 12, 2026--
4Jun 12, 2026--
4Jun 12, 2026--
4Jun 12, 2026--
4Jun 12, 2026--
8-KJun 12, 2026Analysis-
4Jun 12, 2026--

Related Health Care companies

All Health Care →

OCUL SEC filings: frequently asked questions

Are OCUL insiders buying or selling?

In the last 90 days, OCULAR THERAPEUTIX, INC (OCUL) officers, directors and 10% owners reported no open-market purchases and 10 open-market sales worth $1.0 million by 7 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold OCUL stock?

As of September 30, 2026, the largest OCULAR THERAPEUTIX, INC (OCUL) holders among the 13F filers tracked by SignalX were BlackRock ($153.2 million), Vanguard Capital Management LLC ($68.6 million), T. Rowe Price Group ($55.1 million), State Street Corp ($42.8 million), Dimensional Fund Advisors ($22.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was OCUL's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), OCULAR THERAPEUTIX, INC (OCUL) reported revenue of $52.0 million (down 18.5% from FY2024) and a net loss of $265.9 million. Diluted EPS was -$1.42. The figures come from the XBRL data in the 10-K.

What are the main risks in OCUL's latest 10-K?

In the 10-K filed February 5, 2026, OCULAR THERAPEUTIX, INC (OCUL) flagged: Regulatory risk: FDA may require additional trials delaying AXPAXLI approval for wet AMD and diabetic retinal disease. Macroeconomic exposure: $82.5M debt under Barings Credit Facility requires minimum liquidity $20M, royalty fee 3.5% of DEXTENZA sales. (AI summary of the Risk Factors section.)

What did OCUL report in its latest 8-K?

OCULAR THERAPEUTIX, INC (OCUL) filed an 8-K on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results announced for quarter ended September 30, 2026.

What are the latest OCUL SEC filings?

OCULAR THERAPEUTIX, INC (OCUL) filed its latest 10-K annual report on February 5, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and a Form 4 insider filing on November 10, 2026.

What is OCUL's SEC CIK number?

OCULAR THERAPEUTIX, INC (OCUL)'s SEC Central Index Key (CIK) is 1393434. EDGAR lists every OCUL filing under that number.

Ask anything about OCUL

The research agent reads OCUL's filings, financials, insider trades and 13F holders, then answers with sources.